A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Center for Biomedicine and Genetics Bookmark and Share

Center for Biomedicine and Genetics

City of Hope established the Center for Biomedicine and Genetics (CBG) to ensure that its technological innovations are efficiently translated from the research lab to the clinical setting in a cost-effective and expeditious manner.  The center also allows scientific and clinical investigators the freedom to test and refine the most promising new therapeutics. 
 
  • CBG is recognized as the nation's premier academic biologic manufacturing facility (the “gold standard” for such facilities, according to the Food and Drug Administration), and has been lauded by The New York Times for its leading role in devising innovative methods of rapid drug development.
     
  • CBG was founded with generous support from City of Hope’s  National Office Products Industry (NOPI), and is licensed by the state and federal government to produce pharmaceutical-grade therapeutic compounds.
     
  • CBG provides investigators with the isolation, environmental control and security needed for the manufacture of products for human use. It functions as a centralized facility and shared resource, available for multiple investigators both on and off campus.
  • CBG is a founding member of the Association of Academic Biologics Manufacturers (AABM), whose mission is to establish a cooperative network of nonprofit, academic-based biologics manufacturers. The association serves as a national resource that brings together clinical investigators with manufacturing capacity and expertise, develops and shares facility operations knowledge among members, provides quality, manufacturing and regulatory training opportunities, and holds annual meetings.
 
GMP-grade Biologics Production
CBG is designed specifically to accommodate small scale (bench-top) production of GMP-grade biologics, viral and nonviral gene therapeutics and modified patient cell populations to support phase I and II clinical trials at City of Hope.  Adherence to cGMP (current Good Manufacturing Practices) is essential in ensuring the quality and integrity of manufactured biologics.
 
Islet Cell Production
The islet cell production facility at CBG provides isolated islet cells for the islet cell resource centers, which are accelerating the study of islet cell transplantation as a potential cure for type 1 diabetes.
 
Partnership Opportunities
An important component of CBG is our Production Partnership Program, which facilitates the development of innovative biologics created by City of Hope investigators, colleagues and partners to treat patients with cancer, diabetes, viral disease and other life-threatening illnesses, and establishes working relationships with regional biopharmaceutical and academic organizations.

The regulatory expertise and manufacturing skill consistently demonstrated by CBG, coupled with leading-edge bioinformatics and clinical trials groups, makes City of Hope an attractive partner for companies looking to streamline drug development and bring exciting new therapeutic technologies to our patients.
 

About Our Facility

CBG’s two-story, 20,000 square-foot, state-of-the-art secured building features:
 
  • 10,000 square feet of biologics manufacturing space (clean rooms) in three specialized zones:
     
  • Viral vector zone – processes in development include adenovirus, retrovirus, adeno-associated virus, lentivirus
  • DNA and protein production zone – 13 production and purification suites served by dedicated aseptic fill-and-finish with air-handling system for class 100/1000 sterile materials, equipment, glassware autoclave/glasswasher and quarantine areas
  • Cell engineering zone – processes in development include ex vivo T-cell and islet cell manipulation

These zones have separate entries, gowning, air-handling and exits to ensure complete isolation of simultaneous production processes.
  • Water facilities: clinical-grade water generator system (2,000 gallon/day capacity); water for injection steam generator for sterilization
  • Cryogenics storage rooms
  • Irradiator facilities
  • Four-gas storage system
  • Quality Control, Quality Assurance and product release storage and management

In addition, this facility supports phase I and II clinical trials at City of Hope through pilot-scale cGMP (current Good Manufacturing Practices) production of:
 
  • Biologics
  • Viral and nonviral gene therapeutics
  • Modified patient cell populations

The design of the facility allows for these three processes to be performed simultaneously, under cGMP, in functionally isolated areas of the building. Further important features include:
 
  • WFI clean stream
  • BL-3 containment capability
  • Key-card-restricted access
  • Provisions for CO2, medical grade air, N2 or other gases
  • Validated monitoring of all equipment, including HVAC and pressurization equipment

Technological Expertise
While CBG is designed to accommodate a wide variety of biological production and purification processes, specific expertise exists in the following areas:
 
  • AAV/adenovirus and retrovirus production 
  • Plasmid DNA production
  • Monoclonal antibody production
  • Hematopoietic cell purification, transduction and propagation
 

Center for Biomedicine & Genetics

Center for Biomedicine and Genetics

Center for Biomedicine and Genetics

City of Hope established the Center for Biomedicine and Genetics (CBG) to ensure that its technological innovations are efficiently translated from the research lab to the clinical setting in a cost-effective and expeditious manner.  The center also allows scientific and clinical investigators the freedom to test and refine the most promising new therapeutics. 
 
  • CBG is recognized as the nation's premier academic biologic manufacturing facility (the “gold standard” for such facilities, according to the Food and Drug Administration), and has been lauded by The New York Times for its leading role in devising innovative methods of rapid drug development.
     
  • CBG was founded with generous support from City of Hope’s  National Office Products Industry (NOPI), and is licensed by the state and federal government to produce pharmaceutical-grade therapeutic compounds.
     
  • CBG provides investigators with the isolation, environmental control and security needed for the manufacture of products for human use. It functions as a centralized facility and shared resource, available for multiple investigators both on and off campus.
  • CBG is a founding member of the Association of Academic Biologics Manufacturers (AABM), whose mission is to establish a cooperative network of nonprofit, academic-based biologics manufacturers. The association serves as a national resource that brings together clinical investigators with manufacturing capacity and expertise, develops and shares facility operations knowledge among members, provides quality, manufacturing and regulatory training opportunities, and holds annual meetings.
 
GMP-grade Biologics Production
CBG is designed specifically to accommodate small scale (bench-top) production of GMP-grade biologics, viral and nonviral gene therapeutics and modified patient cell populations to support phase I and II clinical trials at City of Hope.  Adherence to cGMP (current Good Manufacturing Practices) is essential in ensuring the quality and integrity of manufactured biologics.
 
Islet Cell Production
The islet cell production facility at CBG provides isolated islet cells for the islet cell resource centers, which are accelerating the study of islet cell transplantation as a potential cure for type 1 diabetes.
 
Partnership Opportunities
An important component of CBG is our Production Partnership Program, which facilitates the development of innovative biologics created by City of Hope investigators, colleagues and partners to treat patients with cancer, diabetes, viral disease and other life-threatening illnesses, and establishes working relationships with regional biopharmaceutical and academic organizations.

The regulatory expertise and manufacturing skill consistently demonstrated by CBG, coupled with leading-edge bioinformatics and clinical trials groups, makes City of Hope an attractive partner for companies looking to streamline drug development and bring exciting new therapeutic technologies to our patients.
 

About Our Facility

About Our Facility

CBG’s two-story, 20,000 square-foot, state-of-the-art secured building features:
 
  • 10,000 square feet of biologics manufacturing space (clean rooms) in three specialized zones:
     
  • Viral vector zone – processes in development include adenovirus, retrovirus, adeno-associated virus, lentivirus
  • DNA and protein production zone – 13 production and purification suites served by dedicated aseptic fill-and-finish with air-handling system for class 100/1000 sterile materials, equipment, glassware autoclave/glasswasher and quarantine areas
  • Cell engineering zone – processes in development include ex vivo T-cell and islet cell manipulation

These zones have separate entries, gowning, air-handling and exits to ensure complete isolation of simultaneous production processes.
  • Water facilities: clinical-grade water generator system (2,000 gallon/day capacity); water for injection steam generator for sterilization
  • Cryogenics storage rooms
  • Irradiator facilities
  • Four-gas storage system
  • Quality Control, Quality Assurance and product release storage and management

In addition, this facility supports phase I and II clinical trials at City of Hope through pilot-scale cGMP (current Good Manufacturing Practices) production of:
 
  • Biologics
  • Viral and nonviral gene therapeutics
  • Modified patient cell populations

The design of the facility allows for these three processes to be performed simultaneously, under cGMP, in functionally isolated areas of the building. Further important features include:
 
  • WFI clean stream
  • BL-3 containment capability
  • Key-card-restricted access
  • Provisions for CO2, medical grade air, N2 or other gases
  • Validated monitoring of all equipment, including HVAC and pressurization equipment

Technological Expertise
While CBG is designed to accommodate a wide variety of biological production and purification processes, specific expertise exists in the following areas:
 
  • AAV/adenovirus and retrovirus production 
  • Plasmid DNA production
  • Monoclonal antibody production
  • Hematopoietic cell purification, transduction and propagation
 

Meet our Staff

Center for Biomedicine & Genetics

Contact Us
For inquiries concerning the CBG manufacturing facility and collaborative opportunities please contact:
 
Larry A. Couture, Ph.D. or
David Hsu, Ph.D.
Center for Applied Technology Development
City of Hope
1500 E. Duarte Road
Duarte, CA 91010
626-256-8728
Center for Applied Technology Development (CATD)
The Sylvia R. and Isador A. Deutch Center for Applied Technology Development (CATD) offers broad expertise in technology transfer and licensing, biologics manufacturing, quality assurance and regulatory affairs.

Beckman Research Institute of City of Hope is internationally  recognized for its innovative biomedical research.
City of Hope is one of only 41 Comprehensive Cancer Centers in the country, the highest designation awarded by the National Cancer Institute to institutions that lead the way in cancer research, treatment, prevention and professional education.
Support Our Research
By giving to City of Hope, you support breakthrough discoveries in laboratory research that translate into lifesaving treatments for patients with cancer and other serious diseases.
 
 
 
 
Learn more about City of Hope's institutional distinctions, breakthrough innovations and collaborations.


NEWS & UPDATES
  • Valentine’s Day is synonymous with dinner reservations, red roses, heart-shaped boxes of chocolates and — more often than not — unrealistically high expectations. Managing those expectations is great advice for all couples on Feb. 14 — and is especially important for couples confronting a cancer diagnosis. Focu...
  • With measles, what starts at a theme park in California definitely doesn’t stay at a theme park in California. Since the beginning of the current measles outbreak – traced to an initial exposure at Disneyland or Disney California Adventure during December – more than 100 people have been diagnosed with a diseas...
  • Even the most loving and secure relationship can be rattled by a life-threatening illness. When a woman is diagnosed with breast cancer, research shows one of the most important factors in helping her cope is having a supportive partner. But that partner can struggle with knowing what to say or how to best supp...
  • It’s been more than a century since Nobel Laureate Paul Ehrlich popularized the idea of a “magic bullet” targeting disease. Cancer researchers ever since have remained in hot pursuit of targeted therapies that home in on cancer cells while leaving normal cells unaffected. Linda Malkas, Ph.D., associate chair of...
  • Cancer patients face a daunting journey marked by challenges and uncertainties. For those undergoing bone marrow, or stem cell, transplantation, one complication poses a particular threat — chronic graft-versus-host disease (GVHD). Now, one researcher may have found a better way to control that threat. GVHD res...
  • Michele Dahlstein, a 50-year-old breast cancer survivor from Upland, California, celebrated her last day of chemotherapy on Dec. 30. She shares her story in her own words: I was diagnosed with breast cancer (invasive ductal carcinoma stage 2) on Aug. 11, 2014, after my yearly mammogram at City of Hope’s W...
  • The treatment of urologic cancers, including bladder cancer, is rapidly evolving. Here, urologic oncologic surgeon and kidney stone specialist Donald Hannoun, M.D., an assistant clinical professor in the Division of Urology and Urologic Oncology at City of Hope | Antelope Valley, explains the changes in hi...
  • A woman confronting metastatic breast cancer faces challenges that, at the outset, seem overwhelming. Research tells us these patients are especially vulnerable to anxiety, depression, hopelessness and other sources of distress. At the same time, they are asked to make complicated choices about their medical ca...
  • California health officials are opting to be safe rather than sorry when it comes to e-cigarettes. The increasingly popular devices are a public health threat, according to a California Department of Health report released Jan. 28. The department is seeking statewide regulation of e-cigarettes, saying they  emi...
  • “Not beyond us.” On World Cancer Day, researchers and caregivers around the globe are embracing this refrain. Specifically, the day calls for action to support healthier lifestyles, early cancer detection, quality of life and access to care. In a time of impressive scientific discovery and narrowing...
  • With more advanced cancer treatments and therapies saving lives every day, it’s safe to say cancer is “Not beyond us,” the official tagline for this year’s World Cancer Day. This year’s World Cancer Day observance takes place on Wednesday, Feb. 4, and focuses on cancer prevention, detection an...
  • Does our environment increase our risk of cancer? What about plastic bottles, radiation, chemicals, soy products …? Do they cause cancer? With so many cancer fears, rumors and downright urban legends circulating among our friends and colleagues, not to mention in the media and blogosphere, why not ask the...
  • With this week’s World Cancer Day challenging us to think about cancer on a global scale, we should also keep in mind that daily choices affect cancer risk on an individual scale. Simply put, lifestyle changes and everyday actions can reduce your cancer risk and perhaps prevent some cancers. According to ...
  • If you haven’t heard the term “precision medicine,” you will. If you don’t have an opinion about access to it, you will. On Friday, President Barack Obama unveiled details of the Precision Medicine Initiative, an effort intended to accelerate cancer research in a powerful way, giving doctors new knowledge and n...
  • The lack of a practical way to produce and store enough stem cells for larger-scale therapies and clinical trials is creating a bottleneck in stem cell research. A new grant to City of Hope from the California Institute for Regenerative Medicine (CIRM) will help solve that problem. The $899,728 grant, awarded T...